BioSpace News Archive

HeartFlow today announced two presentations at the American Heart Association (AHA) conference being held as a virtual meeting on November 13-17, 2020.

CLS Holdings USA, Inc. (OTCQB:CLSH)(CSE:CLSH), the ''Company’’ or ''CLS’’, a diversified cannabis company operating as Cannabis Life Sciences, today announced the financial and operational results for its Nevada wholly-owned subsidiaries for the month of October 2020 with net revenues of $1.787M and Gross Margin of 50.12%.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16 at 4:40 p.m. Eastern Time.

Sunshine Biopharma, Inc. oday announced that it has signed an agreement with JOAH International Pte., Ltd., headquartered in Singapore for distribution of Essential-9tm in Asia and the Far East.

Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced the appointment of Ram Aiyar, Ph.D., MBA, as its chief executive officer. Dr. Aiyar brings nearly 20 years of diverse experience across company-building, biotech and pharma to advance

Study recently published by Penn team in Cell Reports provides evidence that NLY01 has the potential for clinical use in the treatment of glaucoma and potentially other retinal diseases

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the following upcoming investor conferences: Stifel 2020 Virtual Healthcare Conference, taking place on Tuesday, November 17 th , 2020 from 10:00-10:30 a.m. ET. 3 rd Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, December 1 st , 2020 from 8:50-9:35 a.m. ET. Audio webcasts of the presentation

RLYB211 is in Clinical Development for the Prevention of FNAIT, a Potentially Life-Threatening Rare Disorder that Impacts Fetuses and Newborns

Lead antibody - ADG20 - expected to advance to clinical studies in early 2021, offers potential best-in-class treatment and durable protection against SARS-CoV-2 and future coronaviruses

Late Breaker to be Presented by Leading Ocular Oncologist, Carol L. Shields, M.D., Director, Ocular Oncology Service, Wills Eye Hospital A Total of Three Abstracts Highlighting AU-011 Selected for Presentation